Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Bearish
1
Neutral
6
Bullish
7
Bearish
6
Neutral
6
Bullish
34
Bearish
5
Neutral
0
Bullish
27
Discovery themes featuring this stockDiscover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
Novartis India Limited (NIL) is a subsidiary of the Swiss pharmaceutical company Novartis. It primarily operates in manufacturing and marketing drugs across pharmaceuticals, generics, over-the-counter, and animal health products.
Novartis' history is marked by major mergers, starting with the merge of Ciba and Geigy in 1970, leading to the formation of Novartis in 1996 after Sandoz joined. This historical consolidation forms the backbone of their capabilities today.
The company has a strong CSR presence, having partnered with WHO on several health initiatives including malaria and tuberculosis efforts, which underscores their commitment to global health issues.
NIL has initiated several marketing strategies, including the 'Arogya Parivar' program targeting healthcare needs in rural India, highlighting their approach to differentiated healthcare solutions.
The company has engaged in strategic partnerships for distribution, notably with Nutri-Ad International for poultry feed supplements and Johnson & Johnson Limited for veterinary sutures, enhancing their product reach.
Pharmaceuticals & Biotechnology
Pharmaceuticals
4,067 Cr
Low Risk
41.6
36.7
-8.5
5.0
1,777.50
750.00
Sales CAGR
Profit CAGR
ROE
ROCE
Novartis India Ltd (NOVARTIND) is currently trading at 1,657.35 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Novartis India Limited (NIL) is a subsidiary of the Swiss pharmaceutical company Novartis. It primarily operates in manufacturing and marketing drugs across pharmaceuticals, generics, over-the-counter, and animal health products. Novartis' history is marked by major mergers, starting with the merge of Ciba and Geigy in 1970, leading to the formation of Novartis in 1996 after Sandoz joined. This historical consolidation forms the backbone of their capabilities today. The company has a strong CSR presence, having partnered with WHO on several health initiatives including malaria and tuberculosis efforts, which underscores their commitment to global health issues. NIL has initiated several marketing strategies, including the 'Arogya Parivar' program targeting healthcare needs in rural India, highlighting their approach to differentiated healthcare solutions. The company has engaged in strategic partnerships for distribution, notably with Nutri-Ad International for poultry feed supplements and Johnson & Johnson Limited for veterinary sutures, enhancing their product reach.
Over the past 52 weeks, Novartis India Ltd has traded between a low of ₹750.00 and a high of ₹1,777.50. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Novartis India Ltd has a market capitalization of approximately 4,067.19. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Novartis India Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 41.60 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 4,067.19 Cr, Novartis India Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Novartis India Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Novartis India Ltd is 41.60. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Total revenue was Rs 87.55 crore for the quarter ended Jun 25, compared with Rs 92.29 crore in Jun 24.
The sale is part of Novartis AG's global strategy to transform into a pure-play innovative medicines company and follows a strategic review of its assets.
Novartis AG is selling its stake as part of a global strategy to transform into a 'pure-play innovative medicines company,' focusing on patented therapies and streamlining its worldwide operations.
Novartis AG is selling its 70.68% stake as part of a global strategic review to transform into a 'pure-play innovative medicines company' and focus on its core R&D and new drug portfolio.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
149.40 | 4,385 Cr | 30.06 | 2.44 | 0.67 | 7.65 | 10.29 | 5.32 | ||
1258.40 | 4,358 Cr | — | 6.28 | 0.08 | -10.66 | -6.48 | -6.55 | ||
1657.35 | 4,067 Cr | 41.60 | 4.97 | 0.00 | 11.39 | 15.94 | 9.99 | ||
360.50 | 3,928 Cr | 84.23 | 13.65 | 0.19 | 16.22 | 14.47 | 9.27 | ||
539.90 | 3,797 Cr | 46.37 | 1.40 | 0.00 | 2.88 | 3.79 | 6.77 | ||
377.85 | 3,793 Cr | 59.10 | 5.70 | 0.03 | 9.66 | 11.45 | 4.78 | ||
405.05 | 3,693 Cr | 18.94 | 2.38 | 0.49 | 12.58 | 11.51 | 6.92 | ||
| Median: 7 Co. | — | 405.05 | 3,928 Cr | 43.98 | 4.97 | 0.08 | 9.66 | 11.45 | 6.77 |
Financial Results
Novartis India notified exchanges that newspaper advertisements were published on July 24, 2026 announcing the unaudited financial results for the quarter ended June 30, 2026, filed under Regulation 47/30 LODR.
Regulatory/Compliance Filing
Novartis India notified exchanges that newspaper ads were published on July 24, 2026 (Financial Express and Navshakti) for the unaudited financial results for the quarter ended June 30, 2026.
Financial Results
Novartis India Ltd filed unaudited financial results with the limited review report for the quarter ended June 30, 2026 with the stock exchanges.
Financial Results
Novartis India Ltd reported unaudited financial results for quarter ended June 30, 2026: Total income INR 1,125.5 million and profit for the period INR 322.1 million. Limited Review Report attached.
Financial Results
Novartis India Limited Board approved unaudited financial results for quarter ended June 30, 2026 and took on record the limited review report. Meeting held on July 23, 2026.
Financial Results
Novartis India Limited: Board approved unaudited financial results for the quarter ended 30-06-2026 and the Limited Review Report at the Board meeting held on 2026-07-23; results are on the company website.
